News
MEDP
397.56
-2.36%
-9.59
Medpace Holdings Is Maintained at Buy by Guggenheim
Dow Jones · 3h ago
Medpace Holdings Price Target Raised to $464.00/Share From $453.00 by Guggenheim
Dow Jones · 3h ago
Guggenheim Maintains Buy on Medpace Hldgs, Raises Price Target to $464
Benzinga · 3h ago
Medpace Holdings Price Target Raised to $454.00/Share From $446.00 by Baird
Dow Jones · 10h ago
Medpace Holdings Is Maintained at Outperform by Baird
Dow Jones · 10h ago
MEDPACE HOLDINGS INC <MEDP.O>: GUGGENHEIM RAISES TARGET PRICE TO $464 FROM $453
Reuters · 10h ago
Baird Maintains Outperform on Medpace Hldgs, Raises Price Target to $454
Benzinga · 10h ago
U.S. RESEARCH ROUNDUP-Amazon, AmEx, Mattel
Wall Street analysts revise their ratings and price targets on several U.S. Listed companies. Amazon, American Express and Mattel are among the companies. American Express raises target price to $255 from $243. Airbnb, Fiserv and other companies raise their targets for the day.
Reuters · 14h ago
U.S. RESEARCH ROUNDUP-Airbnb, American Express Co, Mattel
Wall Street analysts revise their ratings and price targets on several U.S. Listed companies. American Express Co, Mattel and Amazon.com are among the companies. Analysts raise target prices for American Express, Amazon and Fiserv. Airbnb, American Express and Mattel raise to buy from.
Reuters · 14h ago
Medpace Holdings, Inc. Q1 2024 Financial Report
Press release · 20h ago
Jefferies Upgrades Medpace Holdings (MEDP)
NASDAQ · 21h ago
ENPH, SEDG and MEDP are among after hour movers
Seeking Alpha · 1d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. ABVC BioPharma and Medpace Hldgs stock increased by 5.15%. Fresh2 Group shares fell 12.9% during the session.
Benzinga · 1d ago
Medpace raised to Buy at Jefferies after Q1 earnings beat
Healthcare Medpace raised to Buy at Jefferies after Q1 earnings beat on Tuesday. Contract research organization exceeded Street forecasts with its Q1 2024 earnings. Jefferies upgraded Medpace Holdings to Buy from Hold after the company topped consensus on earnings. The analyst also raised his price target to $450 from $340.
Seeking Alpha · 1d ago
Decoding 5 Analyst Evaluations For Medpace Hldgs
5 analysts have evaluated Medpace Hldgs and provided 12-month price targets. The average target is $437.0. Medpace is a late-stage contract research organization that provides drug development and clinical trial services. The company has an impressive net margin of 15.7%. Medpace has a positive revenue growth rate of 26.47%.
Benzinga · 1d ago
Medpace Holdings Raised to Buy From Hold by Jefferies
Dow Jones · 1d ago
Medpace Holdings Price Target Raised to $450.00/Share From $340.00 by Jefferies
Dow Jones · 1d ago
Jefferies Upgrades Medpace Hldgs to Buy, Raises Price Target to $450
Benzinga · 1d ago
MEDPACE HOLDINGS INC <MEDP.O>: JEFFERIES RAISES TO BUY FROM HOLD; RAISES TARGET PRICE TO $450 FROM $340
Reuters · 1d ago
MEDP Stock Earnings: Medpace Hldgs Beats EPS, Misses Revenue for Q1 2024
Medpace Hldgs reported earnings per share of $3.20 for the first quarter of 2024. The company reported revenue of $511.04 million. This was 0.30% lower than the analyst estimate for revenue. Medpace reported results for the quarter.
Investorplace · 1d ago
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.